3-iodobenzylguanidine has been researched along with Gelineau Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barateau, L; Benkiran, M; Chenini, S; Dauvilliers, Y; Evangelista, E; Jaussent, I; Lopez, R; Mariano-Goulart, D | 1 |
| Christoffersen, C; Ellingsgaard, H; Enevoldsen, LH; Gammeltoft, S; Hovmand, NL; Jennum, PJ; Kjær, A; Stallknecht, BM; Suetta, C; Tindborg, M | 1 |
2 other study(ies) available for 3-iodobenzylguanidine and Gelineau Syndrome
| Article | Year |
|---|---|
Cardiac Sympathetic Activity differentiates Idiopathic and Symptomatic Rapid Eye Movement Sleep Behaviour Disorder.
Topics: 3-Iodobenzylguanidine; Adolescent; Adult; Aged; Aged, 80 and over; Female; Heart; Humans; Iodine Radioisotopes; Male; Mediastinum; Middle Aged; Narcolepsy; Polysomnography; Radionuclide Imaging; REM Sleep Behavior Disorder; Sleep, REM; Young Adult | 2018 |
Functional brown adipose tissue and sympathetic activity after cold exposure in humans with type 1 narcolepsy.
Topics: 3-Iodobenzylguanidine; Adipose Tissue, Brown; Adult; Cold Temperature; Female; Fibroblast Growth Factors; Fluorodeoxyglucose F18; Glucagon-Like Peptide 1; Healthy Volunteers; Humans; Male; Middle Aged; Narcolepsy; Orexins; Positron-Emission Tomography; Thermogenesis; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2018 |